MISSISSAUGA, ON, June 3 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), today announced the appointment of Dr. Nick Glover to the newly created position of President and Chief Operating Officer. Dr. Glover will provide broad leadership to the Company and have primary responsibility for its operations and infrastructure, in particular the development and commercialization of YM's pipeline.
"After the successful merger of Cytopia into YM and with the further support of our investors, we have built YM into a vibrant company with a portfolio of promising late-stage products matched by a strong balance sheet. Given the potential of this outstanding platform, the Board and I believe that this is a critical opportunity in YM's development to similarly strengthen the leadership of the Company," said David Allan, Chairman and CEO of YM BioSciences. "Nick's operational experience, skill-set and leadership style are an ideal fit with YM BioSciences. His experience running a public company, in particular one that conducted international clinical trials in similar cancer indications as nimotuzumab, is a perfect complement for this role. In addition to this expertise, his background in small molecule drug design and his doctoral degree in chemistry are an excellent match for our JAK inhibitor and VDA programs."
Dr. Glover was formerly the President and Chief Executive Officer at Viventia Biotech Inc., a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer. While at Viventia, Dr. Glover led the strategic development of a novel monoclonal antibody discovery platform, advancing three clinical products including a Phase III antibody for the treatment of advanced head and neck
|SOURCE YM BioSciences Inc.|
Copyright©2010 PR Newswire.
All rights reserved